Abstract 94P
Background
Both neoadjuvant carboplatin/paclitaxel (CROSS) and cisplatin/5-fluorouracil (PF) regimens in combination with radiotherapy are significantly effective at improving survival in patients with esophageal cancer. However, the treatment burden differ greatly among the two strategies.
Methods
Our goal is to select the most beneficial neoadjuvant chemoradiotherapy (nCRT) regimen for esophageal squamous cell carcinoma (ESCC) in terms of in- and outpatient visits, adverse events, medical costs and survival outcomes. Both regimens are, by intention, given in an outpatient setting.
Results
From 2012-2020, 232 patients eligible for nCRT were retrospectively collected from two Taiwanese medical centers, 153 patients received CROSS and 79 received PF, the intended radiotherapy dose was 41.4Gy-45Gy. The two groups were comparable in tumor and patient characteristics except for patient’s age (mean age =58.6 ± 8.7 in the CROSS group vs 54.8 ±8.5 in the PF group; P<0.001). More than 80% had clinical stage III or IVa disease. The nCRT completion rates were comparable. Patients in the PF group experienced more nausea, vomiting, diarrhea and dysphagia during nCRT. They lost an average of 4% of body weight after nCRT compared to 1% in the CROSS group (P=0.001). However, patients who received CROSS experienced more lymphocytopenia and leukopenia (P<0.001). Only 20% of all patients in the PF group were never admitted compared to 70% in the CROSS group (P<0.001). Despite the higher costs of chemotherapeutic agents of the CROSS regimen, the two groups had comparable cost expenditures during nCRT. Three-year overall and progression free survival were 48% vs 46% (P=0.39) and 31% vs 20% (P=0.042), in the CROSS and PF group, respectively.
Conclusions
The treatment burden of nCRT according to the CROSS regimen on patients with esophageal cancer was significantly less than the PF regimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02